0
Skip to Content
MD IP
Services
Overseas patent firms
Corporates
Overflow support
Others
Testimonials
About me
Contact
Blog
md@md-ip.com
MD IP
Services
Overseas patent firms
Corporates
Overflow support
Others
Testimonials
About me
Contact
Blog
md@md-ip.com
Folder: Services
Back
Overseas patent firms
Corporates
Overflow support
Others
Testimonials
About me
Contact
Blog
md@md-ip.com
Parameters and (in)sufficiency of disclosure – T 2009/23
EPO case law, EPO oppositions and appeals, EPO T decisions Michał Dąbrówka 22/07/2025 EPO case law, EPO oppositions and appeals, EPO T decisions Michał Dąbrówka 22/07/2025

Parameters and (in)sufficiency of disclosure – T 2009/23

In T 2009/23, the Board of Appeal of the European Patent Office found that a key parameter in the main independent claim could not be reliably determined, leading to fatal insufficiency of disclosure.  Learn more in our latest article.

Read More
T 1065/23 – on novelty and inventive step of pea protein extracts
EPO case law, EPO T decisions, EPO practice Michał Dąbrówka 17/07/2025 EPO case law, EPO T decisions, EPO practice Michał Dąbrówka 17/07/2025

T 1065/23 – on novelty and inventive step of pea protein extracts

T 1065/23 from the EPO’s Technical Board of Appeal illustrates how targeted experimental evidence can make or break product-by-process claims in the chemical field. Learn more in our latest article.

Read More
T 1561/23 - G 1/24 in action
EPO case law, EPO G decisions, EPO T decisions Michał Dąbrówka 10/07/2025 EPO case law, EPO G decisions, EPO T decisions Michał Dąbrówka 10/07/2025

T 1561/23 - G 1/24 in action

In T 1561/23, the Technical Board of Appeal of the European Patent Office applied the principles of G 1/24 on using the description to interpret patent claims. Learn the key takeaways from the decision.

Read More
G 1/23 - reproducibility not a requirement for a commercial product to be prior art
EPO case law, EPO G decisions, EPO oppositions and appeals Michał Dąbrówka 03/07/2025 EPO case law, EPO G decisions, EPO oppositions and appeals Michał Dąbrówka 03/07/2025

G 1/23 - reproducibility not a requirement for a commercial product to be prior art

The Enlarged Board of Appeal finds in G 1/23 that non-reproducible commercial products are part of the state of the art. Learn the key takeaways here.

Read More
Dark blue banner showing a white stylized dopamine molecule graphic to the left of the text “MD” in orange and “IP” in white.

Regulated by IP Reg.

Business Address

Zlota 75A/7
00-819, Warsaw
Poland

Contact

md@md-ip.com
+48 796 328 597